ATE264859T1 - Neue adenosin-monophosphat-deaminase-inhibitoren - Google Patents

Neue adenosin-monophosphat-deaminase-inhibitoren

Info

Publication number
ATE264859T1
ATE264859T1 AT94907992T AT94907992T ATE264859T1 AT E264859 T1 ATE264859 T1 AT E264859T1 AT 94907992 T AT94907992 T AT 94907992T AT 94907992 T AT94907992 T AT 94907992T AT E264859 T1 ATE264859 T1 AT E264859T1
Authority
AT
Austria
Prior art keywords
deeaminase
inhibitors
adenosine monophosphate
new adenosine
compounds
Prior art date
Application number
AT94907992T
Other languages
English (en)
Inventor
Mark David Erion
Brett Carder Bookser
Srinivas Rao Kasibhatla
Harry Edward Gruber
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Application granted granted Critical
Publication of ATE264859T1 publication Critical patent/ATE264859T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Information Transfer Systems (AREA)
AT94907992T 1993-02-03 1994-02-03 Neue adenosin-monophosphat-deaminase-inhibitoren ATE264859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1284193A 1993-02-03 1993-02-03
PCT/US1994/001342 WO1994018200A1 (en) 1993-02-03 1994-02-03 Novel inhibitors of adenosine monophosphate deaminase

Publications (1)

Publication Number Publication Date
ATE264859T1 true ATE264859T1 (de) 2004-05-15

Family

ID=21756974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94907992T ATE264859T1 (de) 1993-02-03 1994-02-03 Neue adenosin-monophosphat-deaminase-inhibitoren

Country Status (10)

Country Link
US (1) US5731432A (de)
EP (1) EP0683781B1 (de)
JP (1) JP3940810B2 (de)
AT (1) ATE264859T1 (de)
AU (1) AU6134994A (de)
CA (1) CA2154577C (de)
DE (1) DE69433722D1 (de)
IL (1) IL108524A0 (de)
MX (1) MX9400874A (de)
WO (1) WO1994018200A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
DK0724587T3 (da) * 1993-09-29 2003-01-06 Nabi Nukleosider og nukleotider med forstørrede ringe
JP2000512663A (ja) * 1996-02-21 2000-09-26 ジボーダン―ルール（アンテルナシヨナル）ソシエテ アノニム フレイグランス先駆体
DE69814089T2 (de) 1997-06-16 2004-02-19 Janssen Pharmaceutica N.V. Verwendung von einem draflazin analog zur schmerzbehandlung
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020086835A1 (en) * 2000-05-22 2002-07-04 Law William R. Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
GB0030424D0 (en) * 2000-12-13 2001-01-24 Pfizer Ltd Crystal structure
AU2002359761A1 (en) * 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
US7386492B2 (en) * 2002-01-15 2008-06-10 Clear Channel Communications, Inc. Inventory and revenue maximization method and system
JP2008534601A (ja) 2005-03-28 2008-08-28 ペリコー セラピューティクス， インコーポレイテッド 患者における副作用を予防または減少するための方法、組成物および処方物
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
DE102007005329A1 (de) * 2007-01-29 2008-07-31 Eberhard-Karls-Universität Tübingen Universitätsklinikum Mittel zur Erythrozytenprotektion
WO2010040110A1 (en) * 2008-10-03 2010-04-08 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
US20100261666A1 (en) * 2009-04-14 2010-10-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of myocardial dysfunction associated with sirs or sepsis
EP2576540B1 (de) 2010-05-26 2019-09-04 Sunovion Pharmaceuticals Inc. Hezeroarylverbindungen und verfahren zur verwendung davon
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US20150031712A1 (en) 2013-03-12 2015-01-29 Moshe Rogosnitzky Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same
US10322129B2 (en) 2015-06-08 2019-06-18 O.D. Ocular Discovery Ltd. Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935505A (en) * 1983-05-03 1990-06-19 Townsend Leroy B Novel azolo [1,3] diazepine-5-ol compounds and their uses
JPS6281387A (ja) * 1985-10-03 1987-04-14 Kitasato Inst:The 新規化合物ｏｍ−３２２３およびその製造法
ATE128141T1 (de) * 1988-03-16 1995-10-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
DE69008906T2 (de) * 1989-03-23 1994-08-25 Pfizer Antiallergische Mittel auf der Basis von Diazepin.
GB8911029D0 (en) * 1989-05-13 1989-06-28 Schering Agrochemicals Ltd Herbicide
EP0601322A3 (de) * 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosindeaminaseinhibitor.
AU6297294A (en) * 1993-02-03 1994-08-29 Gensia, Inc. Adenosine deaminase inhibitor therapies

Also Published As

Publication number Publication date
US5731432A (en) 1998-03-24
CA2154577A1 (en) 1994-08-18
DE69433722D1 (de) 2004-05-27
JPH08506344A (ja) 1996-07-09
AU6134994A (en) 1994-08-29
JP3940810B2 (ja) 2007-07-04
MX9400874A (es) 1994-08-31
EP0683781A1 (de) 1995-11-29
IL108524A0 (en) 1994-05-30
WO1994018200A1 (en) 1994-08-18
EP0683781A4 (de) 1997-05-28
EP0683781B1 (de) 2004-04-21
CA2154577C (en) 2005-08-02

Similar Documents

Publication Publication Date Title
ATE264859T1 (de) Neue adenosin-monophosphat-deaminase-inhibitoren
MX9200294A (es) Inhibidores de cinasa de adenosina
TR199900308T2 (xx) Tiyenopirimidinler
FI945363A (fi) Uusia merkaptoasetyyliamidopyridatso (1,2)pyridatsiini-, pyratsolo(1,2)pyridatsiini-, pyridatso (1,2-a)(1,2)diatsepiini- ja pyratsolo(1,2-a)(1,2)diatsepiinijohdannaisia, jotka ovat käyttökelpoisia enkefalisaasin ja ACE:n estäjinä
DE69611251D1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ES2083595T3 (es) Derivados de indol que inhiben la biosintesis de leucotrienos.
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
ES2118250T3 (es) Combinaciones germicidas de substancias activas.
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ES2157116T3 (es) Composiciones de teñido de fibras queratinicas que contienen 3-aminopirazolo-(1,5-a)-pirimidinas, procedimiento de teñido, 3-aminopirazolo-(1,5-a)-pirimidinas y su procedimiento de preparacion.
DK0889886T3 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
PL338339A1 (en) Novel derivatives of tetrazole
ATE317912T1 (de) Verfahren zur herstellung von beta-lactamen
MY129445A (en) Compositions for treating inflammatory response
DE3369980D1 (en) Disubstituted proline derivatives, process for their preparation and their use
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
NO20011946D0 (no) Mangansammensetninger og fremgangsmåter for MRI
MX9605072A (es) Dispositivo dispensador para pretratamiento.
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
ES8705437A1 (es) Procedimiento para preparar derivados de pirazol-(1,5-a)piridina
ES2040750T3 (es) Un procedimiento para la preparacion de un derivado de isoquinolinol.
ZA949564B (en) Method for treating constipation using dimeticone.
DK0518413T3 (da) Thioxanthenonantitumormidler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties